SCHEMBL5134767

SCHEMBL5134767

CCCCN(Cc1ccc(O)c(OCC)c1)Cc1c(-c2ccccc2OC)nc(-c2ccccc2)n1CCCC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.40
C5AR1 P21730 1/20 0.39
BCL2L2 Q92843 1/20 0.38
HTR1A P08908 1/20 0.36
HTR2C P28335 1/20 0.36
HTR2B P41595 1/20 0.36
KDM4E B2RXH2 1/20 0.35
GAA P10253 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
TAAR1 Q96RJ0 1/20 0.35
SIRT2 Q8IXJ6 1/20 0.35
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
PAX8 Q06710 1/20 0.34
ADRA1D P25100 1/20 0.33
ADRA1A P35348 1/20 0.33
ADRA1B P35368 1/20 0.33
CACNA2D1 P54289 1/20 0.33
DRD2 P14416 1/20 0.33
DRD3 P35462 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5136086 0.95 C5AR1 (0.41) C5AR1BCL2L2HTR1AHTR2CHTR2B
SCHEMBL5136839 0.91 C5AR1 (0.42) C5AR1BCL2L2HTR1AHTR2CHTR2B
SCHEMBL5134684 0.90 C5AR1 (0.41) C5AR1BCL2L2HTR1AHTR2CHTR2B
SCHEMBL5072402 0.89 MAPT (0.43) MAPTC5AR1KDM4ESIRT2MEN1
SCHEMBL648771 0.89 C5AR1 (0.45) C5AR1KDM4EGAASIRT2MEN1
SCHEMBL5136707 0.88 MAPT (0.42) MAPTC5AR1MEN1KMT2ADRD2
SCHEMBL5138077 0.88 C5AR1 (0.39) C5AR1BCL2L2HTR1AHTR2CHTR2B
SCHEMBL5075007 0.88 MAPT (0.44) MAPTC5AR1KDM4EGAAMEN1
SCHEMBL5137101 0.87 BCHE (0.42) C5AR1BCL2L2HTR1AHTR2CHTR2B
SCHEMBL5135984 0.86 BCL2L2 (0.39) C5AR1BCL2L2HTR1AHTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed